Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation.

Cancer gene therapy - 1 Mar 2024

Wang Su He, Cao Zhengyi, Farazuddin Mohammad, Chen Jesse, Janczak Katarzyna W, Tang Shengzhuang, Cannon Jayme, Baker James R

Abstract excerpt

KRAS mutations occur commonly in the lung and can lead to the development of non-small cell lung cancer (NSCLC). While the mutated KRAS protein is a neoantigen, it usually does not generate an effective anti-tumor immune response on mucosal/epithelial surfaces. Despite this, mutated KRAS remains a potential target for immunotherapy since immune targeting of this protein in animal models has been effective at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Lung Neoplasms

Share to Mutation

Share to Peptides

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 38177307
DOI: 10.1038/s41417-023-00717-9

Genes

KRAS
CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation.PMID 38177307Read ↗

DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.Semantic proximity Read ↗

Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.Semantic proximity Read ↗

Production of Lipid-Nanoparticles mRNA Lung Cancer Vaccine and Neutralizing Monoclonal Antibodies to Mutated Forms of KRAS AntigensSemantic proximity Read ↗

Cancer vaccines: Targeting KRAS-driven cancers.Semantic proximity Read ↗

Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention.Semantic proximity Read ↗

Micellar co-delivery of KRAS-mutant inhibitors and TLR7/8 agonists synergizes targeted therapy and immunotherapy in lung cancer.Semantic proximity Read ↗

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine.Semantic proximity Read ↗

Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

Inhalable siRNA Nanoparticles for Enhanced Tumor-Targeting Treatment of KRAS-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

An in silico reverse vaccinology approach to design a novel multiepitope peptide vaccine for non-small cell lung cancersSemantic proximity Read ↗

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.